SARCOGYNNCT07942168
Doxorubicin Plus Dacarbazine Versus Doxorubicin Alone as First-Line Therapy for Metastatic or Recurrent Uterine Leiomyosarcoma
StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
1-year progression-free survival (PFS)
Timeframe: Time from enrollment to disease progression or relapse or death due to any cause, or data cut-off date at 1 year, whichever occured first (up to ~12 months)
Secondary (3)
Overall Survival
Objective Response Rate
incidence of Adverse events
Arms and interventions
DoxorubicinActive comparator
Participants receive 6 cycles of Doxorubicin. Each cycle is 21 days.
Doxorubicin+DacarbazineExperimental
Participants receive 6 cycles of Doxorubicin+Dacarbazine. Each cycle is 21 days.
Drugs: Doxorubicin, dacarbazine
Sites
1 site in 1 country
- Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" оf the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO)Moscow, Russia